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ABSTRACT
A recent systematic literature and meta-analysis reported relative efficacy of trimethoprim-
sulfamethoxazole (TMP-SMX) for the treatment of toxoplasmic encephalitis (TE) in HIV-infected 
adults. Here, we estimated relapse rates during secondary prophylaxis with TMP-SMX, and further 
explored differences in relapse rates prior to introduction of highly active antiretroviral therapy 
(HAART) and the widespread adoption of HAART. A systematic search of PubMed, Embase, and 
Cochrane Central Register of Controlled Trials yielded 707 studies whereby 663 were excluded 
after abstract screening, and 38 were excluded after full review leaving 6 studies for extraction. 
We performed double data extraction with a third-party adjudicator. Study designs varied with 
only one randomized study, four prospective cohorts and one retrospective cohort. Relapse 
rates were transformed using the Freeman-Tukey method and pooled using both fixed-effect 
and random-effects meta-analysis models. The TMP-SMX relapse rate was 16.4% (95% CI = 6.2% 
to 30.3%) based on random-effects models. When the disaggregated pre-HAART studies (n = 4) 
were included, the relapse rate was 14.9% (random effects; 95% CI = 3.7% to 31.9%). Analysis 
of two post-HAART studies indicated a relapse rate of 19.2% (random effects; 95% CI  =  2.8% 
to 45.6%). Comparing the relapse rates between pre- and post-HAART studies were contrary 
to what might be expected based on known benefits of HAART therapy in this population. 
Nevertheless, cautious interpretation is necessary considering the heterogeneity of the included 
studies and a limited number of subjects receiving TMP-SMX reported in the post-HAART era.
Background
A recent systematic literature and meta-analysis reported 
by Hernandez et al. [1], reported relative efficacy of tri-
methoprim-sulfamethoxazole (TMP-SMX) for the treat-
ment of toxoplasmic encephalitis (TE) in patients with 
AIDS [1]. Building on the work of Hernandez et al. [1],we 
quantifiedTE relapse rates during secondary prophylaxis 
with TMP-SMX. Defining relapse rates is an important ele-
ment of patient management as it represents additional 
mortality and morbidity and costs for the healthcare 
system, as well as hospitals. This is particularly challeng-
ing in scenarios where rehospitalization within defined 
periods of time often are not reimbursed by insurers. 
Therefore,rehospitalization costs are paid by the hospital 
without reimbursement.
The aim of this study was to conduct a systematic 
literature review and meta-analysis to estimate relapse 
rates associated with TMP-SMX in secondary prophylaxis 
following improvement of an episode of TE. We further 
assessed relapse rates in the pre- and post- highly active 
antiretroviral therapy (HAART) era.
Methods
Search strategy
The study was conducted following PRISMA guidelines 
[2]. PubMed, Embase, and Cochrane Central Register 
of Controlled Trials (CENTRAL) were searched up to 
November 11, 2016. The search strings for the three data-
bases are available as supplementary data (Appendix 
S1). To be eligible for inclusion, studies had to include 
datafindings on patients with HIV infection or AIDS, 
receiving secondary prophylaxis with TMP-SMX after 
resolution of a prior TE event.Studies needed to report 
© 2017 the author(s). Published by Informa UK limited, trading as taylor & Francis group.
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simplify interpretation independent proportions were 
converted to percentages reflecting relapse rates.
Results
Characteristics of studies
From the initial 707identified studies, 663 were excluded 
based onabstract screening and removal of duplicates. 
An additional38were rejectedafter full text review forthe 
following reasons: being an abstract only (n  =  5), not 
administering a TMP-SMX based regimen (n = 15), not 
providing relapse rates (n = 5), being an epidemiology 
or a switching study (n = 3), not evaluating TE (n = 1), 
being a primary prophylaxis study (n = 3), being a review 
article (n = 2), not being published in English, French, 
Spanish, German or Portuguese (n = 2), andinclusion of 
inappropriate patient population (n = 2).
Study designs varied with only one randomized study, 
four prospective cohortsand one retrospective cohort 
[5678910]. No substantial differences were found in 
administered doses of TMP-SMX for both the acute and 
maintenance treatment phase across studies, except for 
Chaddha et al. [8] in which patients received a combina-
tion of TMP-SMX plus pyrimethamine. Four studies were 
either fully or partly performed in the pre-HAART era 
(n = 135) and two studies were conducted entirely in the 
post-HAART era (n = 100). The follow-up for pre-HAART 
studies was considerably shorter than the follow up for 
post-HAART [pre-HAART: 3 – 9 months; post-HAART 31 
– 36 months].
Quality assesment
The quality of all (n = 6)included studies wasrated as fair, 
with a risk of bias due to lack of blinding, neverthelessthe 
reported relapse outcomes were considered of sufficient 
qualityto be included in the meta-analysis.
Meta-analyses
The forest plot of the six included studies illustrates the 
range of relapse rates observed in the analysis Figure 1.
The combined TMP-SMX relapse rate was 16.4% 
(95%CI = 6.2% to 30.3%) using a random-effects models. 
In a sub analysis in which only the pre-HAART studies 
(n = 4) were included, the relapse rate was14.9% (random 
effects; 95% CI = 3.7% to 31.9%) with I2 = 79.4% (95% 
CI = 11.7% to 90.4%). Analysis of two post-HAART studies 
indicated a relapse rate of 19.2% (random effects; 95% 
CI = 2.8% to 45.6%), I2 values unassessable due to limited 
number of studies (n = 2) Table 2.
Discussion
Pyrimethamine plus sulfadiazine is the preferred regi-
men in secondary prophylaxis and pyrimethamine plus 
on relapse outcomes during maintenance treatment 
and be published in peer-reviewed journals in English, 
Spanish, Portuguese, German or French. Studies in pri-
mary prophylaxis were excluded. Review articles, letters 
to the editor (not being research letters), comments, case 
reports, and preclinical studies were also excluded. Study 
eligibility for inclusion was assessed in duplicate by two 
independent reviewers, and in cases of discrepancy,a 
third reviewer was consulted to reach consensus.
Data extraction
Data extraction was performedin duplicate on all 
included studies to limit human error. A third reviewer 
resolved discrepancies in extracted data between the 
two independent reviewers. Non-English studies were 
translated and extracted. Extracted data included: first 
author, publication year, study design, demographics, 
acute and maintenance treatment regimens, number 
of patients evaluated for relapse, incidence of relapse, 
and time of follow-up.HAART status of studies was deter-
mined by the period of patient enrollment in the study 
(not publication date), either before or after 1996, and 
the reported background anti-retroviral therapy admin-
istered to patients. The meta-analysis consisted of six 
studies representing 235 patients receiving TMP-SMX 
as a secondary prophylaxis for TE (Table 1).
Quality assessment
The study quality assessment tools of the National Heart, 
Lung, and Blood Institute of the National Institutes of 
Health (NIH) for quality assessment of Observational 
Cohort and Cross-Sectional Studies and Controlled 
Intervention Studies were used to assess the quality of 
included studies [3].
Statistical analyses
The primary outcome was rate of relapse associated 
with TMP-SMX maintenance therapy. Relapse rates 
were transformed using the Freeman-Tukey method and 
pooled using both fixed-effect (inverse variance method) 
and random-effects (DerSimonian and Laird method) 
meta-analysis models. The estimate of heterogeneity 
was taken from the inverse variance model and was 
quantified by the I2 consistency score.The I2 describes 
the percentage variation across studies attributed to het-
erogeneity rather than chance. High I2 values (over 75%) 
suggests considerable heterogeneity between studies. 
Scores over 50% are moderate and over 75% suggest the 
need to consider estimates from random-effects models 
[4]. The choice to present fixed or random effects results 
was based on heterogeneity determined by I2.The anal-
ysis was performed using StatsDirect (Altrincham, UK) 
statistical program version 2.8.0 (27 October 2013). To 
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post-HAART which is contrary as one would expect 
HAART to confer benefits. We attribute this to the het-
erogeneity in the clinical study data based on I2 scores 
and a limited number of post-HAART evaluations using 
TMP-SMX (n = 100). In addition, although not included 
in the present systematic review and meta-analysis, poor 
adherence to TMP-SMX secondary prophylaxis seem to 
be the most probable cause of TE relapse [6]. Although 
it is tempting to compare relapse rates between inter-
ventions, as these studies represent independent assess-
ments, a direct comparison is inappropriate here. The 
present analysis identified high I2 value (83%) with large 
interval (CI = 58.3% to 90.4%) reflecting a considerable 
heterogeneity among the included studies, which makes 
it difficult to draw conclusions. On this basis we have 
presented the random effect results.
Similar to the analysis reported by Hernandez et al. 
[1], we included a wide range of study designs in our 
analysis to reflect real-world outcomes for the manage-
ment of secondary prophylaxis [1]. Because the focus of 
our analysis was on relapse rates, it was necessary that 
studies reported follow-up over the maintenance period 
and reported relapse outcomes. We believe this is an 
added dimension to the results reported by Hernandez., 
and can inform relapse rates for TMP-SMX but cautious 
interpretation is necessary due to the heterogeneity 
observed. Larger randomized clinical trials are important 
to obtain a conclusive answer regarding relapse rates 
associated with TMP-SMX for secondary prophylaxis of 
HIV-related TE.
Disclosure statement
The sponsor had no influence on study design or writing of 
the manuscript. AVH and JEV report no conflicts of interest. 
clindamycin is the preferred second-line treatment in 
most guidelines. TMP-SMX and other antibiotic alone 
and in combination are listed as alternative regimens 
[111213].
A previous investigation using a similar protocol to 
the work described here reported pyrimethamine-based 
regimens relapse rates of 19.2% and 11.1% for fixed-ef-
fects models including 1,596 subjects during pre-HAART 
and post-HAART treatment eras, respectively [14].The 
present study identified data of six studies including 
235 patients and a relapse rate of 16.2%. Although the 
total number of included subjects in Connolly et al. 
2017 is higher than the present study, likely reflecting 
the licensed indication of pyrimethamine for the treat-
ment of toxoplasmosis, the previous study also showed 
significant heterogeneity across studies. Considering the 
two studies use independent proportions test we can 
not directly compare the rates of relapse under different 
prophylaxis schemes. Future high quality randomised 
studies should be conducted compare the efficacy of 
pyrimethamine and TMP-SMX.
As reported here, the disaggregated HAART analysis 
did not follow the expected order in that pre-HAART 
relapse rates were not observed to be higher than the 
0.0 0.2 0.4 0.6 0.8
combined 0.1493 (0.0368, 0.3193)
Torre 1998 retrospective 0.0704 (0.0233, 0.1567)
Smadja_1998 (in French) 0.4118 (0.1844, 0.6708)
Chaddah_1999 0.2000 (0.0252, 0.5561)
Torre (1998) RCT 0.0270 (0.0007, 0.1416)
proportion (95% confidence interval)
Figure 1. Forest Plot from the combined analysis of pre- and post-haaRt studies.
Table 2. tMP-sMX maintenance therapy relapse rates based on 
proportions meta-analysis for aggregate Pre- and Post-haaRt 
and individual haaRt periods.
*not assessable, limited studies included.
 
Relapse rate Random 
effects (95% CI) I²
Pre-and Post haaRt 
combined (6 studies)
16.4% 83%
(6.2% to 30.3%) (58.3% to 90.4%)
Pre-haaRt (4 studies) 14.9% 79.4% 
(3.7% 31.9%) (11.7% to 90.4%)
Post-haaRt (2 studies) 19.2% n/a*
(2.8% to 45.6%)
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